Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Operating Expenses (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Operating Expenses over the past 3 years, most recently at $53.7 million for Q4 2025.

  • Quarterly results put Operating Expenses at $53.7 million for Q4 2025, up 114.17% from a year ago — trailing twelve months through Dec 2025 was $138.8 million (down 5.44% YoY), and the annual figure for FY2025 was $138.8 million, down 5.44%.
  • Operating Expenses for Q4 2025 was $53.7 million at Tonix Pharmaceuticals Holding, up from $36.4 million in the prior quarter.
  • Over the last five years, Operating Expenses for TNXP hit a ceiling of $79.5 million in Q2 2024 and a floor of $18.4 million in Q3 2024.
  • Median Operating Expenses over the past 3 years was $30.7 million (2023), compared with a mean of $34.3 million.
  • Biggest five-year swings in Operating Expenses: soared 174.2% in 2024 and later plummeted 61.91% in 2025.
  • Tonix Pharmaceuticals Holding's Operating Expenses stood at $31.1 million in 2023, then dropped by 19.44% to $25.1 million in 2024, then surged by 114.17% to $53.7 million in 2025.
  • The last three reported values for Operating Expenses were $53.7 million (Q4 2025), $36.4 million (Q3 2025), and $30.3 million (Q2 2025) per Business Quant data.